title: Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?
authors.forename: Susana
authors.initials: S
authors.lastname: Banerjee
authors.forename: Stan B
authors.initials: SB
authors.lastname: Kaye
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011379:Prognosis; D059039:Standard of Care
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab